Neumora (NMRA) Executive Chair Paul L. Berns Receives 500,000-Share Award

What Happened

• Paul L. Berns, Executive Chair of Neumora Therapeutics (NMRA), was granted a derivative award for 500,000 shares on August 20, 2026. The filing reports an acquisition price of $0.00 and shows the grant as a derivative instrument (reported value $0). This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-08-20; Form 4 filed: 2026-08-21 (filed the next day).
• Instrument: Derivative award for 500,000 shares, reported at $0.00 acquisition price.
• Shares owned after the transaction: not disclosed in this filing.
• Footnote: 25% of the shares vest on the first anniversary of the August 20, 2026 vesting commencement date; thereafter 1/48th of the total vests monthly so that 100% vests on the fourth anniversary.
• Filing timeliness: reported the next business day; appears timely.

Context

• This is a grant/award (compensation) rather than a purchase or sale; such awards are common for executive compensation and generally vest over time before becoming transferable. The filing does not indicate an immediate exercise or sale.